Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Advances in Hematology & OncologyCases in the Management of Nonmetastatic Castration-Resistant Prostate Cancer: Darolutamide Added to Leuprolide in a 73-Year-Old Patient

In this case, the second in a three-part series, a man was diagnosed with prostate cancer based on a prostate-specific antigen (PSA) level of 6.5 ng/mL. The initial diagnosis was stage 3 disease (T3, N0, M0), with a Gleason score of 3+4=7. The rationale for the treatment decisions is explained, along with the trials (ARAMIS, SPARTAN, PROSPER) that influenced the decisions.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form